- Anticipated increase in electricity consumption as commercial manufacturing activities increase.
- Increased Scope 2 GHGE due to power suppliers increasing their GHGE per unit of electricity supplied.
iX Biopharma Ltd.
Greenhouse gas emissions & sustainability report data
In its July 2023 to June 2024 reporting, iX Biopharma Ltd. disclosed greenhouse gas emissions of 949 t CO2-e. By scope: Scope 2: 949 t CO2-e. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
949 t CO2-e
July 2023 to June 2024
Energy Use
1.1M kWh
July 2023 to June 2024
📊 Emissions by Scope (July 2023 to June 2024)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 949 t CO2-e |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| July 2023 to June 2024 | 949 t CO2-e |
| 2022-07 to 2023-06 | 937 t CO2-e (Scope 2) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Reduced energy consumption by 3% despite a 1% increase in revenue.
- Re-formulated SL-NAD+ wafers to double the dosage, reducing resource consumption and potential waste by half.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Maintain or lower electrical energy per dollar of sales.
🌱 ESG Focus Areas
EnvironmentSocialGovernanceEconomic